D. Boral Capital Reaffirms Buy Rating for Omeros

On Thursday, D. Boral Capital reiterated its "buy" rating for Omeros Corporation (NASDAQ:OMER) in a research report. The firm also set a price target of $36.00 for the company's shares. This target suggests a significant potential upside of approximately 274.61% from the stock's current trading price.

In addition to D. Boral Capital's assessment, other research analysts have been providing insights into Omeros's stock performance. For instance, Rodman & Renshaw initiated coverage of Omeros on November 14th, issuing a "buy" rating with a price target of $9.00. Meanwhile, StockNews.com modified its rating for Omeros, upgrading it from "sell" to "hold" on November 20th. Also, Needham & Company LLC maintained a "hold" rating on the shares as of January 17th, and Cantor Fitzgerald reaffirmed a "neutral" rating on the same date. On the same day, Rodman & Renshaw elevated its rating to a "strong-buy" stance for Omeros.

Currently, the consensus among investment analysts regarding Omeros is a "Moderate Buy," with an average price target of $22.50. This reflects a mix of ratings, as three analysts have a hold rating on the stock, while two have issued buy ratings, and one has given it a strong buy rating.

Omeros's Stock Performance

During trading on Thursday, Omeros's shares increased by $0.36, reaching a price of $9.61. A total of 724,692 shares were traded, which is above the typical trading volume of 507,703 shares. Over the past fifty-two weeks, the stock has seen a low of $2.61 and a high of $13.60. Currently, Omeros's moving averages stand at 50 days of $9.25 and 200 days of $6.69. The company's market capitalization is approximately $556.90 million, and it has a P/E ratio of -4.16. The stock also has a beta value of 1.98, indicating some volatility in its price movements.

Recent Institutional Investments in Omeros

Recently, several institutional investors have adjusted their holdings in Omeros. Truvestments Capital LLC increased its stake in the company by 116.5% during the fourth quarter, now owning 3,102 shares valued at roughly $31,000. Tower Research Capital LLC TRC also expanded its shares by 79.0%, resulting in ownership of 4,467 shares worth about $44,000. Additionally, Quantbot Technologies LP entered a new position in Omeros, worth around $46,000.

BNP Paribas Financial Markets raised its stake by 130.6% in the third quarter, bringing its total to 12,388 shares valued at approximately $49,000 after acquiring more this quarter. Picton Mahoney Asset Management significantly boosted its holdings by 692.5% during the fourth quarter, now owning 5,040 shares valued around $50,000 after adding 4,404 shares last quarter. In total, institutional investors hold about 48.79% of Omeros's stock.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical firm focused on discovering, developing, and commercializing targeted therapeutics. Their efforts predominantly center on treating immunologic diseases, which include complement-mediated diseases, various cancers, and problems connected to addiction and compulsive disorders. Notable products in development include Narsoplimab (OMS721/MASP-2), which has completed its pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA). Currently, this product is undergoing a Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and a Phase II clinical trial for COVID-19 treatment.

Omeros, Stock, Investment